Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinoma

FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinomaПодробнее

FIGHT-202: pemigatinib for FGFR2 altered CCAПодробнее

FGFR2 Inhibitors in Advanced CholangiocarcinomaПодробнее

Impact of prior systemic therapy on PFS patients enrolled in FIGHT-202Подробнее

FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangementПодробнее

Advances in FGFR inhibition for hepatobiliary cancerПодробнее

The rapid growth of FGFR2 inhibitors: pemigatinib in FIGHT-202Подробнее

Therapeutic Management of Biliary Cancers: Integrating Precision Medicine With Targeted StrategiesПодробнее

FIGHT-202: pemigatinib in CCAПодробнее

Promising future for cholangiocarcinoma diagnosis and treatmentПодробнее

Embracing the Era of Individualized Therapy in Advanced Biliary CancersПодробнее

2018 Cholangiocarcinoma Foundation Annual Conference #10 - Day 2 - FGFR SignalingПодробнее

Webinar: Targeting the FGFR pathway: Infigratinib in cholangiocarcinomaПодробнее

The promise of pemigatinib for patients with FGFR1-rearranged MLNПодробнее

FGFR Inhibitor Clinical TrialsПодробнее

Final results from ClarIDHy: ivosidenib in IDH1-mutated CCAПодробнее

Webinar: First-in Human-Studies of FGFR Inhibitor KIN-3248 and RAF Inhibitor KIN-2787Подробнее

Insights into pemigatinib and the recent FDA approval of this agentПодробнее

Webinar: TT-00420 TreatmentПодробнее